Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son

Just four months af­ter scor­ing its first can­cer drug ap­proval in a decade, Sanofi is stay­ing on the on­col­o­gy of­fen­sive.

The French phar­ma is plan­ning …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.